Back to Search
Start Over
N -Glycoprofiling of SLC35A2-CDG: Patient with a Novel Hemizygous Variant.
- Source :
-
Biomedicines [Biomedicines] 2023 Feb 16; Vol. 11 (2). Date of Electronic Publication: 2023 Feb 16. - Publication Year :
- 2023
-
Abstract
- Congenital disorders of glycosylation (CDG) are a group of rare inherited metabolic disorders caused by a defect in the process of protein glycosylation. In this work, we present a comprehensive glycoprofile analysis of a male patient with a novel missense variant in the SLC35A2 gene, coding a galactose transporter that translocates UDP-galactose from the cytosol to the lumen of the endoplasmic reticulum and Golgi apparatus. Isoelectric focusing of serum transferrin, which resulted in a CDG type II pattern, was followed by structural analysis of transferrin and serum N -glycans, as well as the analysis of apolipoprotein CIII O -glycans by mass spectrometry. An abnormal serum N -glycoprofile with significantly increased levels of agalactosylated (Hex3HexNAc4-5 and Hex3HexNAc5Fuc1) and monogalactosylated (Hex4HexNAc4 ± NeuAc1) N -glycans was observed. Additionally, whole exome sequencing and Sanger sequencing revealed de novo hemizygous c.461T > C (p.Leu154Pro) mutation in the SLC35A2 gene. Based on the combination of biochemical, analytical, and genomic approaches, the set of distinctive N -glycan biomarkers was characterized. Potentially, the set of identified aberrant N -glycans can be specific for other variants causing SLC35A2-CDG and can distinguish this disorder from the other CDGs or other defects in the galactose metabolism.
Details
- Language :
- English
- ISSN :
- 2227-9059
- Volume :
- 11
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Biomedicines
- Publication Type :
- Academic Journal
- Accession number :
- 36831116
- Full Text :
- https://doi.org/10.3390/biomedicines11020580